Invention Grant
US08008449B2 Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
有权
程序性死亡1（PD-1）的人单克隆抗体和单独使用抗PD-1抗体或与其他免疫治疗剂组合治疗癌症的方法
- Patent Title: Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
- Patent Title (中): 程序性死亡1（PD-1）的人单克隆抗体和单独使用抗PD-1抗体或与其他免疫治疗剂组合治疗癌症的方法
-
Application No.: US11913217Application Date: 2006-05-02
-
Publication No.: US08008449B2Publication Date: 2011-08-30
- Inventor: Alan J. Korman , Mohan Srinivasan , Changyu Wang , Mark J. Selby , Bingliana Chen , Josephine M. Cardarelli
- Applicant: Alan J. Korman , Mohan Srinivasan , Changyu Wang , Mark J. Selby , Bingliana Chen , Josephine M. Cardarelli
- Applicant Address: US NJ Princeton JP Osaka
- Assignee: Medarex, Inc.,Ono Pharmaceutical Co., Ltd.
- Current Assignee: Medarex, Inc.,Ono Pharmaceutical Co., Ltd.
- Current Assignee Address: US NJ Princeton JP Osaka
- Agency: Baker Botts L.L.P.
- International Application: PCT/JP2006/309606 WO 20060502
- International Announcement: WO2006/121168 WO 20061116
- Main IPC: C07K16/28
- IPC: C07K16/28
Abstract:
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Public/Granted literature
Information query
